APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 5, 2003, Pages 1181-1189

  Pereira, Cândida F ^a   Paridaen, Judith T M L ^a   van de Bovenkamp, Marja ^a   Middel, Jeena ^a   Verhoef, Jan ^a   Nottet, Hans S L M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Calcusyn; MT 2 cell line; o (acetoxyphenyl)hept 2 ynyl sulphide; Peripheral blood mononuclear cells

Indexed keywords

2 (ACETOXYPHENYL)HEPT 2 YNYL SULFIDE; ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; MONONUCLEAR CELL; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN;

DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPTANES; HIV CORE PROTEIN P24; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NEUTROPHILS; REVERSE TRANSCRIPTASE INHIBITORS; SULFIDES;

EID: 0038440771     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg176     Document Type: Article

References (60)

1. De Clercq, E. (2000). Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Reviews in Medical Virology 10, 255-77.
2. Tavel, J. A., Miller, K. D. & Masur, H. (1999). Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clinical Infectious Diseases 28, 643-76.
3. Richman, D. D. (2001). HIV chemotherapy. Nature 410, 995-1001.
4. Baba, M. (1997). Cellular factors as alternative targets for inhibition of HIV-1. Antiviral Research 33, 141-52.
5. Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P. et al. (1995). Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 171, 1411-9.
6. Maxeiner, H. G., Keulen, W., Schuurman, R., Bijen, M., de Graaf, L., van Wijk, A. et al. (2002). Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients. Journal of Infectious Diseases 185, 1070-6.
7. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J. et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51-8.
8. Huang, H., Chopra, R., Verdine, G. L. & Harrison, S. C. (1998). Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282, 1669-75.
9. Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J. et al. (1999). Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13, 2349-59.
10. Notermans, D. W., van Leeuwen, R. & Lange, J. M. (1996). Treatment of HIV infection. Tolerability of commonly used antiretroviral agents. Drug Safety 15, 176-87.
11. Mansky, L. M. (1996). The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 222, 391-400.
12. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-6.
13. Lipsky, J. J. (1996). Antiretroviral drugs for AIDS. Lancet 348, 800-3.
14. Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S. et al. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 337, 7251-33.
15. Mocroft, A., Vella, S., Benfield, T. L., Chiesi, A., Miller, V., Gargalianos, P. et al. (1998). Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352, 1725-30.
16. Palella, F. J., Jr, Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 338, 853-60.
17. Henry, K., Erice, A., Tierney, C., Balfour, H. H., Jr, Fischl, M. A., Kmack, A. et al. (1998). A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 19, 339-49.
18. Chou, T. C. & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 22, 27-55.
19. Maga, G., Hubscher, U., Pregnolato, M., Ubiali, D., Gosselin, G. & Spadari, S. (2001). Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and D- and L-(beta)-dideoxynucleoside triphosphate analogs. Antimicrobial Agents and Chemotherapy 45, 1192-200.
20. Deminie, C. A., Bechtold, C. M., Stock, D., Alam, M., Djang, F., Balch, A. H. et al. (1996). Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrobial Agents and Chemotherapy 40, 1346-51.
21. Villahermosa, M. L., Martinez-Irujo, J. J., Cabodevilla, F. & Santiago, E. (1997). Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides. Biochemistry 36, 13223-31.
22. Tremblay, C., Merrill, D. P., Chou, T. C. & Hirsch, M. S. (1999). Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates. Journal of Acquired Immune Deficiency Syndromes 22, 430-6.
23. Snyder, S., D'Argenio, D. Z., Weislow, O., Bilello, J. A. & Drusano, G. L. (2000). The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrobial Agents and Chemotherapy 44, 1051-8.
24. Carr, A., Miller, J., Law, M. & Cooper, D. A. (2000). A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14, F25-32.
25. Max, B. & Sherer, R. (2000). Management of the adverse effects of antiretroviral therapy and medication adherence. Clinical Infectious Diseases 30, Suppl. 2, S96-116.
26. Monno, L., Appice, A., Cavaliere, R., Scarabaggio, T. & Angarano, G. (1999). Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations. Journal of Infectious Diseases 180, 568-71.
27. de Jong, J. J., Goudsmit, J., Lukashov, V. V., Hillebrand, M. E., Baan, E., Huismans, R. et al. (1999). Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 13, 75-80.
28. Rousseau, M. N., Vergne, L., Montes, B., Peeters, M., Reynes, J., Delaporte, E. et al. (2001). Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 26, 36-43.
29. Maga, G. & Spadari, S. (2002). Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations. Current Drug Metabolism 3, 73-95.
30. Daelemans, D., Vandamme, A. M. & De Clercq, E. (1999). Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antiviral Chemistry and Chemotherapy 10, 1-14.
31. Lori, F., Jessen, H., Lieberman, J., Clerici, M., Tinelli, C. & Lisziewicz, J. (1999). Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Research and Human Retroviruses 15, 619-24.
32. Martin, M., Serradji, N., Dereuddre-Bosquet, N., Le Pavec, G., Fichet, G., Lamouri, A. et al. (2000). PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. Antimicrobial Agents and Chemotherapy 44, 3150-4.
33. Rozera, C., Carattoli, A., De Marco, A., Amici, C., Giorgi, C. & Santoro, M. G. (1996). Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely infected human cells. Evidence for a transcriptional block. Journal of Clinical Investigation 97, 1795-803.
34. Bourinbaiar, A. S. & Lee-Huang, S. (1995). The non-steroidal anti-inflammatory drug, indomethacin, as an inhibitor of HIV replication. FEBS Letters 360, 85-8.
35. Macilwain, C. (1993). Aspirin on trial as HIV treatment. Nature 364, 369.
36. Kalgutkar, A. S., Crews, B. C., Rowlinson, S. W., Garner, C., Seibert, K. & Marnett, L. J. (1998). Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 280, 1268-70.
37. Pereira, C. F., Paridaen, J. T. M. L., Rutten, K., Huigen, M. C. D. G., van de Bovenkamp, M., Middel, J. et al. (2003). Aspirin-like molecules that inhibit human immunodeficiency virus-1 replication. Antiviral Research, in press.
38. Kalgutkar, A. S., Kozak, K. R., Crews, B. C., Hochgesang, G. P. J. & Marnett, L. J. (1998). Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. Journal of Medicinal Chemistry 41, 4800-18.
39. McKeating, J. A., McKnight, A. & Moore, J. P. (1991). Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. Journal of Virology 65, 852-60.
40. Moore, J. P., McKeating, J. A., Weiss, R. A. & Sattentau, Q. J. (1990). Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250, 1139-42.
41. Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P. et al. (1988). Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 20, 309-21.
42. Chou, T. C. & Hayball, M. P. (1996). CalcuSyn: Windows Software for Dose Effect Analysis. BIOSOFT, Cambridge, UK.
43. Jeeninga, R. E., Keulen, W., Boucher, C., Sanders, R. W. & Berkhout, B. (2001). Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. Virology 283, 294-305.
44. Boucher, C. A., Keulen, W., van Bommel, T., Nijhuis, M., de Jong, D., de Jong, M. D. et al. (1996). Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrobial Agents and Chemotherapy 40, 2404-9.
45. Essey, R. J., McDougall, B. R. & Robinson, W. E., Jr (2001). Mismatched double-stranded RNA (polyl-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. Antiviral Research 51, 189-202.
46. Greco, W. R., Bravo, G. & Parsons, J. C. (1995). The search for synergy: a critical review from a response surface perspective. Pharmacological Reviews 47, 331-85.
47. Georgiou, N. A., van der Bruggen, T., Jansen, C. A. Oudshoorn, M., Nottet, H. S., Marx, J. J. et al. (2001). The chemotherapeutic agent bleomycin in a two-drug combination with zidovudine, ritonavir or indinavir synergistically inhibits HIV type-1 replication in peripheral blood lymphocytes. International Journal of Antimicrobial Agents 18, 513-8.
48. Chong, K. T. & Pagano, P. J. (1997). In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrobial Agents and Chemotherapy 41, 2367-73.
49. Lamarre, D., Croteau, G., Wardrop, E., Bourgon, L., Thibeault, D., Clouette, C. et al. (1997). Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrobial Agents and Chemotherapy 41, 965-71.
50. Buckheit, R. W., Jr, Russell, J. D., Xu, Z. Q. & Flavin, M. (2000). Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication. Antiviral Chemistry and Chemotherapy 11, 321-7.
51. King, R. W., Klabe, R. M., Reid, C. D. & Erickson-Viitanen, S. K. (2002). Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrobial Agents and Chemotherapy 46, 1640-6.
52. Piras, G., Nakade, K., Yuasa, S. & Baba, M. (1997). Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. AIDS 11, 469-75.
53. Carr, A., Vella, S., de Jong, M. D., Sorice, F., Imrie, A., Boucher, C. A. et al. (1996). A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. AIDS 10, 635-41.
54. Brennan, T. M., Taylor, D. L., Bridges, C. G., Leyda, J. P. & Tyms, A. S. (1995). The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Research 26, 173-87.
55. Esnouf, R., Ren, J., Ross, C., Jones, Y., Stammers, D. & Stuart, D. (1995). Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Structural Biology 2, 303-8.
56. Drusano, G. L., D'Argenio, D. Z., Symonds, W., Bilello, P. A., McDowell, J., Sadler, B. et al. (1998). Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrobial Agents and Chemotherapy 42, 2153-9.
57. Pagano, P. J. & Chong, K. T. (1995). In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. Journal of Infectious Diseases 171, 61-7.
58. Ludovici, D. W., Kukla, M. J., Grous, P. G., Krishnan, S., Andries, K., de Bethune, M. P. et al. (2001). Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). Bioorganic and Medicinal Chemistry Letters 11, 2225-8.
59. Ludovici, D. W., Kavash, R. W., Kukla, M. J., Ho, C. Y., Ye, H., De Corte, B. L. et al. (2001). Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Bioorganic and Medicinal Chemistry Letters 11, 2229-34.
60. Ludovici, D. W., De Corte, B. L., Kukla, M. J., Ye, H., Ho, C. Y., Lichtenstein, M. A. et al. (2001). Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorganic and Medicinal Chemistry Letters 11, 2235-9.